Miguel-Angel Perales, MD

Articles

Transplant Complications and Survival Outcomes

January 19th 2024

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

January 19th 2024

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

January 19th 2024

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

Role of Allogeneic Transplants in Hematologic Malignancies

December 15th 2023

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

Dr. Perales on the Future of CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 10th 2019

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Dr. Perales on CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 3rd 2019

Miguel-Angel Perales, MD, discusses the use of CAR T-cell therapy in diffuse large B-cell lymphoma and transformed follicular lymphoma.

Dr. Perales on Ongoing Studies With CAR T Cells in DLBCL

November 16th 2019

Miguel-Angel Perales, MD, discusses replacing autologous stem cell transplant with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Perales on Treatment With Approved CAR T-Cell Therapy

January 31st 2018

Miguel-Angel Perales, MD, Deputy Chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses determining which chimeric antigen receptor (CAR) T-cell therapy to use for patients with hematologic malignancies.

Dr. Perales on Remaining Questions With CAR T-Cell Therapy in Hematologic Malignancies

June 24th 2017

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with CAR T-cell therapy in hematologic malignancies.

Dr. Perales on the PROGRESS II Trial in Hematologic Malignancies

December 22nd 2016

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, provides an overview of the PROGRESS II trial, which was conducted for patients with hematologic malignancies.

Dr. Perales on GVHD and T Cell Depletion

January 29th 2014

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan-Kettering Cancer Center, discusses graft-versus-host disease (GVHD) and T cell depletion.